Covista Inc.
Rank #157Capital ReturnCVSA · NYSE · Consumer Defensive
Covista Inc. (CVSA) — Rank #157 by gross profitability (GP/assets 0.37) · ROE 17.4% · Piotroski F-Score 6 / 9.
As-of 2026-09-15 · CIK 0000730464 · all metrics point-in-time as of the filing date.
About
Covista Inc., together with its subsidiaries, provides healthcare education in the United States, Barbados, St.
Show moreShow less
Kitts, and St. Maarten. It operates in three segments: Chamberlain, Walden, and Medical and Veterinary. The company provides degree programs, including bachelor's, master's, and doctoral degrees; and online certificate programs for nursing, health professions, medical, and veterinary postsecondary education, counseling, business, information technology, psychology, public health, social work and human services, public administration and public policy, and criminal justice. It also operates Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. The company was formerly known as Adtalem Global Education Inc. and changed its name to Covista Inc. in February 2026. Covista Inc.
was incorporated in 1987 and is headquartered in Chicago, Illinois.
- Industry
- Education & Training Services
- Sector
- Consumer Defensive
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- June 30
- Website
- covista.com
Financials
Strengthening
Direction over 5 fiscal years
- Free cash flowimproving
- Gross marginstable
- Gross profitabilityimproving
- Net cashimproving
- Operating marginimproving
- Return on equitystable
- Share count (dilution)stable
Monitoring diagnostic of business direction — not a prediction of returns.
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2026-06-30filed 2026-08-06 | 2025-06-30filed 2025-08-07 | 2024-06-30filed 2024-08-06 | 2023-06-30filed 2023-08-10 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 1,954.1 | 1,788.3 | 1,584.7 | 1,450.8 |
| Revenue growth (YoY) | 9.3% | 12.9% | 9.2% | 5.0% |
| Gross profit | 1,120.4 | 1,016.9 | 886.1 | 802.3 |
| Gross margin | 57.3% | 56.9% | 55.9% | 55.3% |
| Net income | 251.6 | 237.1 | 136.8 | 93.4 |
| Net margin | 12.9% | 13.3% | 8.6% | 6.4% |
| EPS (diluted) | $7.04 | $6.18 | $3.39 | $2.05 |
| EPS growth (YoY) | 13.9% | 82.3% | 65.4% | — |
| Cash flow | ||||
| Operating cash flow | 470.4 | 337.9 | 295.8 | 202.9 |
| Capital expenditures | 77.7 | 50.3 | 48.9 | 37.0 |
| Free cash flow | 392.7 | 287.6 | 246.9 | 165.9 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?